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Abstract
Parkinson’s disease (PD) is a progressive neurodegenerative disease characterized by the predominantly dopaminergic neu-
ronal black matter degeneration. The multicentre study of PRIAMO (PaRkinson & non Motor symptom) showed that in 98.6 % of 
cases, non-motor symptoms (NMS) were observed in patients with PD. Cognitive impairment is one of the most common NMS PD. 
According to these studies, cognitive dysfunction develops in most patients at an early stage of the disease, with mild to moderate 
cognitive impairment. In the later stages of the disease, dementia occurs in 80 % of patients with PD. 
Aim of the research. To study the peculiarities of cognitive impairment in patients with PD and autoimmune thyroiditis 
(AIT), their association with motor and non-motor disorders, and to assess the impact on the quality of life of patients.
Materials and methods of the research. 109 patients with PD aged 47 to 75 years were examined. The main group consisted 
of patients with IA and IB subgroups, control – IIA and IIB subgroups. General clinical and neurological examinations, evaluation of 
motor functions by the Unified Parkinson’s disease Rating Scale (UPDRS), neuropsychological testing (MMSE, MoCA, FAB, BDI), 
Hamilton’s Alert Scale (HARS), scale used for assessing autonomic disorders in patients with PD and Parkinson’s disease question-
naire (PDQ-39), statistical analysis using the “Statistica 6.0” program.
Results. Neuropsychological testing showed that MMSE, MoCA, and FAB obtained from patients with PD and AIT are lower 
compared to patients with PD. Analyzing the indicators of MMSE, FAB, and MoCA scales in dynamics, a statistically significant difference 
was found in subgroups of IB and IIB; in subgroups of IA and IIA – was not observed. During the analysis of the results of the neuropsy-
chological testing, no association was found at the statistically significant level in the subgroups of IA and IB between the duration of the 
disease and MMSE, MoCA, and FAB scales. In the IA subgroup, in the initial review, feedback was observed on a statistically significant 
level of average strength between the level of anxiety and the indicator of the MMSE scale, an indicator of the MoCA scale. In the IA sub-
group, there was no relationship at the statistically significant level between the indicators of neuropsychological testing (MMSE, MoCA, 
FAB) and motor and non-motor manifestations (depression, vegetative disorders). There was a connection at a statistically significant level 
between the indicators of neuropsychological testing (MMSE, MoCA, FAB) and motor and non-motor manifestations of PD in patients who 
received anti-parkinsonian therapy for a long period of time. The negative influence of the level of cognitive impairments on the quality of 
life of patients with PD and AIT was revealed, indicating the high medical and social significance of these violations.
Conclusions. Neuropsychological testing showed that MMSE, MoCA, FAB scores in patients with PD and AIT (IB sub-
group) were lower compared to patients with PD (IIB subgroup). There was a connection at a statistically significant level between 
the indicators of neuropsychological testing (MMSE, MoCA, FAB) and motor and non-motor manifestations of PD in patients who 
received anti-parkinsonian therapy for a long period of time. The negative influence of the level of cognitive impairments on the 
quality of life of patients with PD and AIT was revealed, indicating the high medical and social significance of these violations.
Keywords: Parkinson’s disease, autoimmune thyroiditis, cognitive impairment, depression, anxiety, autonomic disorders, 
motor disorders, quality of life.
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Parkinson’s disease (PD) is a progressive neurodegenerative disease characterized by the 
degeneration of predominantly dopaminergic neurons of the black substance [1]. Before the first 
motor manifestations of PD occur, about 40–60 % of dopaminergic neurons are lost. The period 
of the disease during which the neurodegenerative process progresses in the absence of classical 
motor symptoms is called the “prodromal phase of PD” [2]. During the “prodromal phase of PD”, 
a wide range of non-motor symptoms (NMSs) is observed: vegetative, sensory, cognitive, affec-
tive, behavioral and psychotic disorders [3, 4]. The multicentric study of PRIAMO (PaRkinson & 
non Motor symptom) showed that in 98.6 % of cases, NMS was observed in patients with PD [5]. 
Cognitive impairment is one of the most common PDs NMS. [6]. According to these studies, cog-
nitive dysfunction develops in most patients at an early stage of the disease, with mild to moderate 
cognitive impairment. Patients have neurodynamic disorders in the form of slowness, astonity 
(bradyphenia), decreased attention, functional capacity and regulatory disturbances that reflect 
dysfunction of the frontal lobes [7, 8]. In the later stages of the disease, dementia occurs in 80 % of 
patients with PD [9, 10]. The development of dementia is associated with a decrease in the effec-
tiveness of antiparkinsonian drugs, an increase in axial motor disturbances (postural instability, 
hardening, hypomimia, dystonia, dysarthria, bradykinesia, camptocormia, autonomic dysfunction, 
sleep disturbances) [7].
Cognitive impairment is one of the main factors that affects the quality of life of patients, 
dramatically aggravates and makes it impossible to care for the family; worsen the outlook and 
dramatically increase the risk of developing dopaminergic psychotic disorders in the background 
of therapy [11].
2. Aim of the research
To study the peculiarities of cognitive impairment in patients with PD and autoimmune 
thyroiditis (AIT), their association with motor and non-motor disorders, and to assess the impact 
on the quality of life of patients.
3. Materials and methods of the research
The research was conducted at the Department of Neurology No. 1 of the Shupyk National 
Medical Academy of Postgraduate Education in 2014–2018. A set of patients took place during 
a consultative review of the direction of the neurologists in the city of Kyiv and the Kyiv region, 
in the neurological department of the Kyiv City Clinical Hospital No. 9, in the neurological de-
partment No. 1 of the Kyiv City Clinical Hospital No. 8. A comprehensive clinical-paraclinical 
examination of 109 patients with PD aged 47 to 75 years (mean age 61.9±0.6). The main group 
consisted of patients with IA and IB subgroups, control – IIA and IIB subgroups. The IA subgroup 
consisted of 22 patients (mean age 57.68±1.06) with PD and AIT who did not receive pathogenetic 
antiparkinsonian therapy; subgroup of IB – 37 patients (mean age 63.65±0.76) with PD and AIT, 
which for a long period received pathogenetic antiparkinsonian therapy; subgroup IIA – 23 patients 
(mean age 58.17±1.35) on PD who did not receive pathogenetic antiparkinsonian therapy; sub- 
group IIb – patients with prolonged duration of PD, who were on antiparkinsonian therapy, in a 
number of 27 people (mean age 66.11±1.02). The diagnosis of Parkinson’s disease was determined 
in accordance with the clinical and diagnostic criteria of the Brain Bank of the British Society of 
Parkinson’s Disease, according to which Parkinsonism can be diagnosed in the presence of akine-
sia (bradykinesia) and one of the symptoms: rigidity of muscles, resting tremor, or postural insta-
bility, which more often joins on more late stages of the disease, not related to the primary visual 
impression, vestibular, cerebellar, proprioceptive dysfunction. 
General clinical and neurological examinations, evaluation of motor functions by the Uni-
fied Parkinson’s disease Rating Scale PD (UPDRS), neuropsychological testing (MMSE, MoCA, 
FAB, BDI), Hamilton’s Alert Scale (HARS), scale used for assessing autonomic disorders in pa-
tients with PD and Parkinson’s disease questionnaire (PDQ-39).
In the statistical analysis, the program “Statistica 6.0” was used. Data processing and anal-
ysis was carried out in OpenOffice software packages (Base, Calc, Writer, Draw, Math), GNU 
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Octave (with preservation of *.doc, *.xls files) – open source software, its use is regulated by the 
license GPL (General Public License) and IBM SPSS from cloud. The quantitative values were 
represented as median (Me), interquartile scope (IQR: Q1–Q3), also determined the scope (Range: 
min-max). When comparing the two groups, the Mann-Whitney (U) criterion was used for inde-
pendent groups. For the analysis of the direction and the strength of the relationship between the 
quantitative indicators, the method of correlation analysis was used to calculate the Spirman cor-
relation coefficient (ρ).
4. Results of the research
Comparing the results of the neuropsychological testing of the IA subgroup with the re-
sults of the IIA subgroup in the primary examination revealed statistically significant lower rates 
in the subgroup IA: FAB (Me 16.0; IQR: 15.0–17.0; Range: 15.0–18.0; Me 17.0; IQR: 17.0–18.0; 
Range : 15.0–18.0; U=145.5; p=0.011). MoCA (Me 25.5; IQR: 25.0–26.0; Range: 25.0–27.0 and 
Me 26.0; IQR: 26.0–27.0; Range: 25.0–30.0; U=162.5; p=0.028). the clock drawing test (Me 7.5; 
IQR: 6.0–9.0; Range: 5.0–10.0; Me 9.0; IQR: 9.0–10.0; Range: 7.0–10.0; U=111.5; p=0.001).
Analyzing the MMSE scale in the subgroup of IA and IIA in the primary examination 
(Me 27.0; IQR: 26.8–28.0; Range: 26.0-28.0; Me 27.0; IQR: 27.0–30.0; Range: 26.0–30.0; U=178.0; 
p=0.075 ) and a year later (Me 27.0; IQR: 26.8–28.0; Range: 26.0–28.0 and Me 27.0; IQR: 27.0–
30.0; Range: 26.0–30.0; U=178.0; p=0.075); no statistically significant difference was detected. 
Indicators of neuropsychological tests in patients with PD, depending on the presence of AIT in the 
primary review, are presented in Table 1
Table 1
Indicators of neuropsychological tests in patients with PD depending on the presence of AIT in the primary 
examination
Scale
ІА subgroup ІB subgroup ІІА subgroup ІІB subgroup
Q1 Q1 Q1 Q1
Me Min Me Min Me Min Me Min
Q3 Max Q3 Max Q3 Max Q3 Max
MMSE (points)
26.8 25.0 27.0 26.0
27.0 26.0 26.0 23.0 27.0 26.0 27.0 25.0
28.0 28.0 26.5 27.0 30.0 30.0 27.0 28.0
FAB (points)
15.0 14.0 17.0 15.0
16.0 15.0 15.0 14.0 17.0 15.0 16.0 14.0
17.0 18.0 15.0 17.0 18.0 18.0 17.0 18.0
MoCA (points)
25.0 24.0 26.0 25.0
25.5 25.0 25.0 22.0 26.0 25.0 25.0 24.0
26.0 27.0 25.5 27.0 27.0 30.0 26.0 27.0
The clock drawing 
test (points)
6.0 7.0 9.0 7.0
7.5 5.0 7.0 5.0 9.0 7.0 9.0 7.0
9.0 10.0 8.5 9.0 10.0 10.0 9.0 9.0
Phonetic speed of 
speech (words)
9.0 7.0 9.0 9.00
9.5 8.0 8.0 6.0 10.0 8.0 9.00 6.0
11.0 15.0 9.0 11.0 12.0 12.0 11.00 14.0
Postponed memory 
(words)
2.0 2.0 2.0 2.0
3.0 1.0 2.0 2.0 3.0 2.0 2.0 2.0
3.0 3.0 3.0 3.0 3.0 5.0 3.0 4.0
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After 1 year, the data of neuropsychological testing in patients with IA and IIA subgroups 
deteriorated, statistically significant lower values were stored in the subgroup IA: FAB (Me 16.0; 
IQR: 15.0–17.0; Range: 15.0–17.0; Me 17.0; IQR: 17.0–18.0; Range: 15.0–18.0; U=132.5; p=0.004). 
MoCA (Me 25.0; IQR: 25.0–26.3; Range: 24.0–27.0 and Me 26.0; IQR: 26.0–27.0; Range: 25.0–
30.0; U=152.0; p=0.017); clock drawing test (Me 6.5; IQR: 5.8–9.0; Range: 5.0–10.0 and Me 9.0; 
IQR: 8.0–10.0; Range: 7.0–10.0; U=110.5; p=0.001).
By analyzing the sub-tests of the MoCA scale (phonetic speed of speech, postponed mem-
ory), no statistically significant difference was found between the indices of the IA and IIA sub-
groups in the initial examination (phonetic speed of speech: Me 9.5; IQR: 9.0–11.0; Range: 8.0–15.0 
and Me 10.0; IQR: 9.0–12.0; Range: 8.0–12.0; U=206.0; p=0.27), postponed memory: Me 3.0; IQR: 
2.0–3.0; Range: 1.0–3.0 and Me 3.0; IQR: 2.0–3.0; Range: 2.0–5.0; U=226.0, p=0.5).
After 1 year, there was no statistically significant difference between the sub-tests of the 
MoCA scale in the subgroups of IA and IIA (phonetic speech rate: Me 8.5; IQR: 7.0–11.0; Range: 
7.0–13.0 and Me 10.0; IQR: 10.0–11.0; Range: 7.0–11.0; U=170.0; p=0.06), postponed memory: 
Me 3.0; IQR: 2.0–3.0; Range: 2.0–3.0 and Me 3.0; IQR: 2.0–3.0; Range: 2.0–5.0; U=252.0, p=0.98).
The analysis of the results of the neuropsychological testing in the subgroups IB and IB in 
the initial survey showed statistically significant lower rates in the subgroup IB: MMSE (Me 26.0; 
IQR: 25.0–26.5; Range: 23.0–27.0 and Me 27.0; IQR: 26.0–27.0; Range: 25.0–28.0; U=260.5; 
p=0.001). FAB (Me 15.0; IQR: 14.0–15.0; Range: 14.0–17.0 and Me 16.0; IQR: 15.0–17.0; Range: 
14.0–18.0; U=276.0; p=0.002). MoCA (Me 25.0; IQR: 24.0–25.5; Range: 22.0–27.0; Me 25.0; 
IQR: 25.0–26.0; Range: 24.0–27.0; U=308.5; p=0.007), clock drawing test (Me 7.0; IQR: 7.0–8.5; 
Range: 5.0–9.0 and Me 9.0; IQR: 7.0–9.0; Range: 7.0–9.0; U=284.5; p=0.002).
After 1 year, statistically significant lower neuropsychological tests were observed in IB 
subgroup patients compared to the IIB subgroup: MMSE (Me 25.0; IQR: 24.0–26.0; Range: 23.0–
27.0 and Me 26.0; IQR: 26.0–27.0; Range: 24.0–28.0; U=190.0, p=0.001). FAB (Me 14.0; IQR: 
14.0–15.0; Range: 13.0–16.0 and Me 16.0; IQR: 15.0–16.0; Range: 14.0–17.0; U=217.0; p=0.001). 
MoCA (Me 24.0; IQR: 23.0–25.0; Range: 22.0–26.0 and Me 25.0; IQR: 24.0–25.0; Range: 24.0–
27.0; U=303.0; p=0.005), the clock drawing test (Me 7.0; IQR: 6.0–8.0; Range: 6.0–9.0 and Me 8.0; 
IQR: 7.0–8.0; Range: 6.0–9.0; U=308.5; p=0.007). Indicators of neuropsychological tests in patients 
with PD depending on the presence of AIT in a year are shown in Table 2.
Table 2
Indicators of neuropsychological tests in patients with PD depending on the presence of AIT in a year
Scale
ІА subgroup ІB subgroup ІІА subgroup ІІB subgroup
Q1 Q1 Q1 Q1
Me Min Me Min Me Min Me Min
Q3 Max Q3 Max Q3 Max Q3 Max
1 2 3 4 5 6 7 8 9
MMSE (points)
26.8 24.0 27.0 26.0
27.0 26.0 25.0 23.0 27.0 26.0 26.0 24.0
28.0 28.0 26.0 27.0 30.0 30.0 27.0 28.0
FAB (points)
15.0 14.0 17.0 15.0
16.0 15.0 14.0 13.0 17.0 15.0 16.0 14.0
17.0 17.0 15.0 16.0 18.0 18.0 16.0 17.0
MoCA (points)
25.0 23.0 26.0 24.0
25.0 24.0 24.0 22.0 26.0 25.0 25.0 24.0
26.3 27.0 25.0 26.0 27.0 30.0 25.0 27.0
The clock drawing 
test (points)
5.8 6.0 8.0 7.0
6.5 5.0 7.0 6.0 9.0 7.0 8.0 6.0
9.0 10.0 8.0 9.0 10.0 10.0 8.0 9.0
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1 2 3 4 5 6 7 8 9
Phonetic speed of 
speech (words)
7.0 6.0 10.0 8.0 7.0
8.5 7.0 7.0 5.0 10.0 7.0 8.0
11.0 13.0 8.0 9.0 11.0 11.0 10.0 11.0
Postponed memory 
(words)
2.0 2.00 2.0 2.0
3.0 2.0 2.00 1.0 3.0 2.0 2.0 2.0
3.0 3.0 3.00 3.0 3.0 5.0 3.0 4.0
Analyzing the indicator of the MMSE scale in dynamics, a statistically significant differ-
ence was found in the subgroups of IB (z=–3.95, p=0.001) and ІІB (z=–2.27, p=0.02), in subgroups 
of IA (z=0.001, p=1.0) and ІІА (z=–0.001, p=1.0) – was not observed (Fig. 1).
Fig. 1. The MMSE scale indicator in the dynamics subgroups
In the subgroups of the IB (z=–3.56, p=0.001) and ІІB (z=–3.16, p=0.002), a statistically 
significant difference of the FAB indicator in the dynamics was revealed. In IA (z=–0.33, p=0.74) 
and ІІА (z=0.001, p=1.00) – it was not observed (Fig. 2).
Fig. 2. The FAB scale indicator in the dynamics subgroups
Comparing the MoCA index with dynamics, a statistically significant difference was found 
in the subgroups of IB (z=–3.95, p=0.001) and IIB (z=–2.45, p=0.014). In subgroups of IA (z=–1.13, 
p=0.26) and ІІА (z=0.001, p=1.00) – not observed (Fig. 3).
Fig. 3. The scale of the MoCA in the subgroups of the comparison in dynamics
The analysis of the clock drawing test in the dynamics showed a statistically significant 
difference in the subgroups of the IA (z=–2.45, p=0.014), IB (z=–2.45, p=0.014). In the sub-
 
 





























































groups IIA (z=–1.41, p=0.16) and IIB (z=–1.36, p=0.15), no statistically significant difference 
was detected.
Comparing sub-tests of the MoCA scale (phonetic speed of speech, postponed memory), 
statistically significant lower values of the phonetic speed of the language of the IB subgroup were 
found compared to the IIB subgroup in the initial examination (Me 8.0; IQR: 7.0–9.0; Range: 
6.0–11.0 and Me 9.0; IQR: 9.0–11.0; Range: 6.0–14.0; U=254.5; p=0.001) and a year later (Me 7.0; 
IQR: 6.0–8.0; Range: 5.0–9.0; Me 8.0; IQR: 8.0–10.0; Range: 7.0–11.0; U=231.0; p=0.001).
Comparing the MoCA, postponed memory of IB and IB subgroup metrics in the primary 
review (Me 2.0; IQR: 2.0–3.0; Range: 2.0–3.0 and Me 2.0; IQR: 2.0–3.0; Range: 2.0–4.0); and a 
year later (Me 2.0; IQR: 2.0–3.0; Range: 1.0–3.0 and Me 2.0; IQR: 2.0–3.0; Range: 2.0–4.0). No 
statistically significant difference was found (U=466.0, p=0.59 and U=430.0, p=0.27, respectively).
Analyzing the sub-tests of the scale of MoCA (phonetic speed of speech, postponed mem-
ory) in dynamics, certain features were revealed. There was a statistically significant difference in 
the indicators of the phonetic speed of the language in the subgroups of the IA (z=–3.50, p=0.001), 
IB (z=–4.44, p=0.001), ІІB (z=–3.37, p=0.001 ); In the IIIA subgroup, no statistically significant 
difference was found (z=–1.50, p=0.13). Analysis of the indicator of delayed memory in the dy-
namics showed a statistically significant difference in subgroups IA (z=–2.00, p=0.046) and IB 
(z=–2.45, p=0.014). In the subgroups IIA (z=0.001, p=1.00) and IIB (z=–1.41, p=0.16), no statisti-
cally significant difference was detected.
During the analysis of the results of the neuropsychological testing, there was no associa-
tion at the statistically significant level in the subgroups of IA and IB between the duration of the 
disease and the MMSE scale (ρ=0.32, p=0.06 and ρ=0.31, p=0.06 respectively), the indicator of 
the FAB scale (ρ=0.31, p=0.16 and ρ=0.009, p=0.96, respectively), the indicator of the MoCA scale 
(ρ=0.34, p=0.12 and ρ=0.22, p=0.18, respectively), an indicator of the phonetic speed of the lan-
guage (ρ=0.42, p=0.05 and ρ=0.13, p=0.44), the index of postponed memory (ρ=0.21, p=0.45 and 
ρ=0.3, p=0.07); there was a direct connection at a statistically significant level of average strength 
between the duration of the disease and the index of the clock drawing test (ρ=0.51, p=0.03 and 
ρ=0.39, p=0.02).
In the IA subgroups, a direct correlation was found between the statistically significant 
level of average strength between the age of the onset of the disease and the MMSE scale (ρ=0.32, 
p=0.048), the index of the MoCA scale (ρ=0.42, p=0.045), the indicator the scale of the FAB 
(ρ=0.44, p=0.04), the index of the clock drawing test (ρ=0.46, p=0.03), the index of phonetic speed 
of the speech (ρ=0.51, p=0.02 ); There was no observed relationship at the statistically significant 
level between the age of the onset of the disease and the amount of delayed memory (ρ=0.17, 
p=0.45). In the IB subgroup, there was no statistically significant relationship between the age of 
the onset of the disease and the MMSE scale (ρ=–0.26, p=0.25), the FAB (ρ=0.21, p=0.22), indi-
cator of the MoCA scale (ρ=0.20, p=0.23); an indicator of the phonetic speed of speech (ρ=0.20, 
p=0.23), an indicator of postponed memory (ρ=0.21, p=0.21); A direct connection was found at a 
statistically significant level of average strength between the age of the onset of the disease and the 
clock drawing test (ρ=0.44, p=0.007).
In the IA subgroup, during the primary examination and after a year, no link was found at 
the statistically significant level between the level of depression and the indicator of the MMSE 
scale (ρ=0.20, p=0.36 and ρ=0.29, p=0.18, respectively ), the index of the MoCA scale (ρ=0.20, 
p=0.38 and ρ=0.13, p=0.56, respectively), the index of the FAB scale (ρ=0.03, p=0.90 and 
ρ=–0.10, p=0.67, respectively). In the IA subgroup, in the initial review, feedback was observed 
at a statistically significant level of average strength between the level of anxiety and the MMSE 
scale (ρ=–0.60, p=0.003), the index of the MoCA scale (ρ=–0.46, p=0.03); between the Hamilton 
scale and the FAB scale was not detected (ρ=0.04, p=0.88). A year later, in the IA subgroup, there 
was no observed correlation between the level of anxiety and the indicator of the MMSE scale 
(ρ=0.35, p=0.18), the index of the MoCA scale (ρ=0.13, p=0.56), an indicator of the FAB scale 
(ρ=–0.46, p=0.11).
The analysis of the relationship between the general indicator of autonomic disturbances 
and the indicator of the MMSE scale (ρ=–0.10, p=0.66), the indicator of the MoCA scale (ρ=0.07, 
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p=0.75), the FAB (ρ=–0.34, p=0.12) did not reveal a statistically significant difference in the IA 
subgroup in the primary examination. A year later there was a feedback on a statistically significant 
level of average strength between the general indicator of vegetative disorders and the FAB scale 
(ρ=–0.59, p=0.004); between the general index of vegetative scale and the MMSE scale (ρ=–0,004, 
p=0.99), the indicator of the MoCA scale (ρ=–0.12, p=0.59) of communication at the statistically 
significant level was not found.
In the IA subgroup, during the primary examination and after a year, no link was found 
at the statistically significant level between the overall score scale UPDRS and the MMSE scale 
(ρ=–0.06, p=0.80 and ρ=–0.08, p=0.72, respectively), the indicator of the MoCA scale (ρ=–0.26, 
p=0.25 and ρ=–0.24, p=0.29, respectively), the index of the FAB scale (ρ=–0.42, p=0.05 and 
ρ=0.21, p=0.34, respectively).
In the IA subgroup, during the primary examination and after a year, a direct correlation 
was found between the statistically significant level of the strong force between the total quality 
of life of patients on PD (PDQ-39) and the MMSE scale (ρ=0.97, p=0.001 and ρ=0.90, p=0.001, 
respectively), the indicator of the MoCA scale (ρ=0.87, p=0.001 and ρ=0.85, p=0.001, respectively); 
a direct connection at a statistically significant level of average strength between the total quality of 
life of patients on PD and the FAB scale (ρ=0.45, p=0.03 and ρ=0.44, p=0.03, respectively).
Statistically significant feedback of average strength was found in the IB subgroup at the pri-
mary examination and one year between the Beck scale score and the MMSE test result (ρ=–0.97, 
p=0.001 and ρ=–0, 90, p=0.001, respectively), the indicator of the MoCA scale (ρ=–0.56, p=0.001 
and ρ=–0.54, p=0.001, respectively), the index of the FAB scale (ρ=–0.40, p=0.045 and ρ=–0.32, 
p=0.045, respectively).
Feedback was received at a statistically significant level of average strength in the IB sub-
group in the primary examination and one year between the level of anxiety and the MMSE scale 
(ρ=–0.52, p=0.001 and ρ=–0.35, p=0, 03, respectively), the indicator of the MoCA scale (ρ=–0.55, 
p=0.001 and ρ=–0.54, p=0.001, respectively), the index of the FAB scale (ρ=–0.40, p=0.045 and 
ρ=0.54, p=0.001, respectively).
There was a feedback on a statistically significant level of average strength in the IB sub-
group during primary examination and one year between the general indicator of autonomic dis-
turbances and the MMSE scale indicator (ρ=–0.65, p=0.001 and ρ=P=0.001, respectively), the indi-
cator of the MoCA scale (ρ=–0.66, p=0.001 and ρ=–0.64, p=0.001, respectively), FAB scale index 
(ρ=–0.44, p=0.01 and ρ=–0.42, p=0.01, respectively).
In the subgroup IB at the initial review and after a year, feedback was found on a statisti-
cally significant average power level between the total score scale of the UPDRS and the MMSE 
scale indicator (ρ=–0.4, p=0.02 and ρ=–0.38, p=0.02 respectively), the indicator of the MoCA scale 
(ρ=–0.38, p=0.02 and ρ=–0.64, p=0.001, respectively), the indicator of the FAB (ρ=–0.42, p=0.01 
and ρ=–0.44, p=0.01, respectively).
In the subgroup of IB during the initial review and after a year, feedback was found on a 
statistically significant average power level between the total patient quality of life (PDQ–39) and 
the MMSE scale (ρ=–0.47, p=0.003 and ρ=–0.40, p=0.01, respectively), the indicator of the MOS 
scale (ρ=–0.34, p=0.04 and ρ=–0.36, p=0.03, respectively). We did not notice a connection at a 
statistically significant level in the primary review and after a year between the total quality of life 
of patients on PD and the FAB score (ρ=0.02, p=0.93 and ρ=–0.10, p=0.54, respectively).
5. Discussion of the results
Studies show that in 80 % of cases, dementia develops with a PD duration of more than 
20 years. Dementia can be manifested in the form of dementia with Lewy bodies, neurodegener-
ation of dopaminergic and cholinergic cortical areas. Investigations of volumetric magnetic reso-
nance imaging showed a posterior-cortical area atrophy in patients with moderate cognitive im-
pairment and dementia [13]. Diffusion-tensor magnetic resonance imaging can detect changes in 
the white matter of the brain in the initial stages of cognitive deficits in patients with PD [14, 15]. 
Studies conducted on posthumous sections of the brain showed a significant loss of cholinergic 
neurons of subcortical nuclei, and surviving neurons contained inclusion, the body of Lewy. The 
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activity of acetylcholinesterase, a presynaptic cholinergic marker, is significantly reduced in the 
frontal cortex in patients with dementia and without cognitive impairment in PD compared to the 
control group. There is a statistically significant relationship between the activity of cortical ace-
tylcholinesterase and MMSE scale [16]. Another study showed cholinergic dysfunction of parietal 
and occipital areas in patients with PD, which did not show cognitive impairment [17]. In a study 
by Fengler S. and co-authors, it is shown: the reduction of the executive function can be considered 
an additional NMP of the prodromal phase of PD [18].
Our study showed moderate cognitive impairment and dementia in PD patients, depending 
on the duration of the disease. The lower rates of neuropsychological testing were observed in 
patients with PD and AIT. The high incidence of cognitive impairment in patients with PD is con-
firmed by previous clinical trials [8, 9].
We found a connection at a statistically significant level between the indicators of neuropsy-
chological testing and NMS PD (anxiety, depression) in patients who received long-term antipar-
kinsonian therapy. A clinical study conducted by Nodel and co-authors shows a statistically signifi-
cant relationship between the level of anxiety and the decrease in the control of cognitive functions, 
attention. There was also a link between the level of depression and the subjective evaluation of 
cognitive functions, especially in the early stages of the disease, while the link between self-esteem 
of cognitive impairment and objective changes (memory impairment) was statistically significant 
at deployed 3 stage PD. The pathophysiological basis of the relationship between cognitive and 
emotional-affective disorders may be different. Cognitive impairment and emotional-affective dis-
turbances can be symptoms of a disease that develops in parallel with common pathophysiological 
mechanisms. Cognitive impairment can exacerbate or even cause anxiety and depression, and, 
conversely, emotional and affective disorders can negatively affect cognitive function [19].
Clinical significance of NMP is determined not only by the high frequency, but also by the 
degree of negative impact on the quality of life of patients. In one of the first studies of the impact 
of various PD symptoms on quality of life, a population-based Australian study showed that after 
15 years of disease, the leading predictor of poor quality of life, besides depression, is dementia, 
which has a higher risk of extinction of psychosis [20]. Our study found a negative effect of the 
level of cognitive impairment on the quality of life of patients with PD and AIT, which is generally 
consistent with the results of a number of recent studies [21]. According to the results of a survey 
of patients with a recent diagnosis of PD, negative effects on quality of life, other than depression, 
anxiety, also carry out attention disorder and memory [22].
Such a significant effect of cognitive impairment on the quality of life of patients with PD 
causes the need for their diagnosis and appropriate correction.
6. Conclusions
1. Neuropsychological testing showed that the MMSE, MoCA, and FAB scores in patients 
with PD and AIT are lower in comparison with patients with PD.
2. There was a statistically significant difference in the dynamics of cognitive impairment 
in patients receiving long-term antiparkinsonian therapy.
3. There was a linkage between statistically significant levels of neuropsychological testing 
(MMSE, MoCA, FAB) and motor and non-motor manifestations of PD in patients receiving long-
term antiparkinsonian therapy.
4. The negative influence of the level of cognitive impairment on the quality of life of patients 
with PD and AIT was revealed, indicating the high medical and social significance of these violations.
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